PBIRx®
Intelligent Solutions in Pharmacy Benefits
612 Wheelers Farms Road, Milford, CT 06461
(888) 797-2479
The recent media coverage of Mylan’s EpiPen® Auto-Injector brand pricing has given rise to many changes and options in the adult and pediatric epinephrine device marketplace, including Mylan’s new lower cost generic. In recent weeks, CVS began marketing the Impax Laboratories generic epinephrine equivalent to Amedra Pharmaceuticals’ Adrenaclick®. Coming in February, Kaléo will be marketing the return of the Auvi-Q® Auto-Injector, a product once marketed by Sanofi Pharmaceuticals prior to a voluntary recall in October 2015.
Depending on the Pharmacy Benefit Manager, the changes to an Employer’s pharmacy drug coverage may include:
Exclusions for brand name epinephrine devices (i.e. Cigna, United Healthcare) only allowing payment for a generic;
A Preferred Tier with a Plan Sponsor rebate for generic and brand epinephrine devices;
A Maximum Allowable Charge (MAC) for a generic equivalent epinephrine device and allowing the patient to select a product.
Table 1 shows the options for generic and brand name epinephrine devices that are currently available or will be available in February 2017.
Table 1. Epinephrine Devices in 2 Pen Quantities per Box
Brand Name
|
Active Ingredient
|
Manufacturer
|
NDC
|
EpiPen® Auto-Injector
EpiPen Jr.® Auto-Injector
|
Epinephrine Injection USP
0.3 mg and 0.15 mg
|
Mylan
|
0.3 mg - 49502-500-02
0.15 mg – 49502-501-02
|
Generic Equivalent to EpiPen®
|
Epinephrine Injection USP 0.3 mg and 0.15 mg
|
Mylan
|
0.3 mg - 49502-102-02
0.15 mg - 49502-101-02
|
Adrenaclick® Auto-Injector
|
Epinephrine Injection USP 0.3 mg and 0.15 mg
|
Amedra Pharmaceuticals
|
0.3 mg – 52054-804-02
0.15 mg – 52054-803-02
|
Generic Equivalent to Adrenaclick® Auto-Injector
|
Epinephrine Injection USP 0.3 mg and 0.15 mg
|
Impax Laboratories
|
0.3 mg - 54505-102-02
0.15 mg – 54505-101-02
*single pens also available
|
Auvi-Q® Auto-Injector
|
Epinephrine Injection USP 0.3 mg and 0.15 mg
|
Kaléo
|
0.3 mg – 60842-023-01
0.15 mg – 60842-022-01
|
Epinephrine is used as a life-saving treatment for patients requiring emergency treatment from allergic reactions including anaphylaxis. Anaphylaxis results from exposure to an allergen, such as nuts or venom from a bee sting, which causes the body to release a flood of chemicals from the immune system. Signs and symptoms of anaphylaxis include a skin rash, nausea and vomiting and a rapid, weak pulse. This immune reaction can lead to shock from a drop in blood pressure and narrowing of the airway, blocking normal breathing. Anaphylaxis requires an immediate trip to the emergency room and injection(s) of epinephrine. Without immediate treatment, anaphylaxis can lead to unconsciousness or death.
As always, cost will be the driver for epinephrine device selection by both patients and insurers. PBIRx can discuss with clients how to manage these epinephrine device options by analyzing current utilization and implementing cost savings programs. Our dedicated pharmacists are developing strategies to offer our clients and their members the best savings available in the marketplace.
PBIRx, an independent pharmacy-focused company, provides analytical, consulting and auditing services utilizing a strong Clinical Department with state of the art technology to advocate for the Plan Sponsor and their employees. Our clinical recommendations benefit both the Plan Sponsor and the employees versus the profitability for the pharmacy benefits manager.
PBIRx has been exclusively providing intelligent solutions to clients in the management of pharmacy benefit costs since 1993. With a staff that includes IT personnel, actuaries, financial analysts, clinical pharmacists, attorneys, HIPAA Compliance Officers and many more experts, PBIRx’s mission is to create optimal health care outcomes while minimizing overall health care costs. For more information, please visit www.pbirx.com or call (888) 797-2479.
